Turn ASCO data into business-critical insights. 30 high-prescribing hem/oncs analyze 8-10 RCC abstracts to help you prepare for what’s next. Take the guesswork out of understanding changes in prescribing behavior for axitinib, pembrolizumab, cabozantinib, lenvatinib, nivolumab, telaglenastat, tivozanib among others. Get your 60+ slide report.

Renal Cell Carcinoma Report
ASCO 2021

American Society of Clinical Oncology

Virtual Meeting
Jun 4 to Jun 8

Share: